• If you are wondering whether Doximity's current share price reflects its true worth, the recent numbers give you plenty to think about.
• The stock closed at US$21.16, with returns of 7.1% over 7 days, 14.6% over 30 days, 51.1% year to date and 59.0% over the last year. These figures may catch the eye of anyone weighing potential risk and reward.
• Recent coverage has focused on Doximity's position within healthcare services and how its digital platform fits into broader trends in clinician communication and workflow tools. That context helps frame why sentiment around the stock has shifted over different time frames.
• Doximity currently holds a 5 out of 6 valuation score. The rest of this article will compare what different valuation methods suggest about the shares, then finish with a more holistic way to judge whether the price makes sense for you.

Approach 1: Doximity Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s dollars to estimate what the business might be worth right now.

For Doximity, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is reported at about $306.6 million. Analyst and extrapolated estimates suggest free cash flow figures between roughly $307.8 million and $642.3 million over the next decade, with one of the later projections for 2031 at $500.3 million. All figures are in US$ and are below $1b, so they are discussed in millions.

Bringing these projected cash flows back to today, Simply Wall St’s model arrives at an estimated intrinsic value of about $49.82 per share. Compared with the recent share price of $21.16, this output implies the shares are 57.5% undervalued according to this DCF framework.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Doximity is undervalued by 57.5%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Approach 2: Doximity Price vs Earnings

For profitable companies, the P/E ratio is a common way to gauge how much you are paying for each dollar of earnings. This makes it a straightforward check on whether a share price feels stretched or reasonable.

Higher growth expectations and lower perceived risk usually support a higher “normal” P/E ratio, while slower expected growth and higher risk tend to justify a lower multiple. Doximity currently trades on a P/E of 16.33x, compared with the Healthcare Services industry average of about 28.27x and a peer group average of 30.42x, so the stock sits below these broad benchmarks.

Simply Wall St’s Fair Ratio is a proprietary estimate of what the P/E might be, given factors such as earnings growth metrics, industry, profit margins, market cap and specific risks. Because it blends these company specific drivers rather than relying on broad group averages, it can be more tailored than a simple industry or peer comparison. For Doximity, the Fair Ratio is 20.24x, which is higher than the current 16.33x P/E, suggesting the shares are trading below this fair value estimate on an earnings basis.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Doximity Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring your view of Doximity’s business story together with a simple financial forecast and a Fair Value, then compare that to the current price to help you assess whether the stock looks appealing. All of this is available inside the Simply Wall St Community page, where millions of investors share and update these story-driven models as news, earnings and guidance arrive.

In practice, one investor might build a Doximity Narrative that aligns with the more bullish analysts, using assumptions that lead to a Fair Value near US$56.00 or within the US$56.00 to US$78.58 range. Another investor might anchor to the more cautious end around US$25.00. Both can see on screen how their story translates into revenue, earnings and margin forecasts, how that rolls into Fair Value, and how their view compares with the current share price and with other Narratives that update as fresh information comes through.

Do you think there's more to the story for Doximity? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.